Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(10):1348–1352. doi: 10.1038/bjc.1997.559

High-resolution HLA-DRB1 and DQB1 genotyping in Japanese patients with testicular germ cell carcinoma.

E Ozdemir 1, Y Kakehi 1, M Mishina 1, O Ogawa 1, Y Okada 1, D Ozdemir 1, O Yoshida 1
PMCID: PMC2228160  PMID: 9374382

Abstract

We report for the first time the frequency distributions of HLA-DRB1 and -DQB1 genes in 55 patients with testicular germ cell carcinoma (TGC) using the modified PCR-RFLP method and compare the results with those for 1216 healthy Japanese control subjects. The modified PCR-RFLP method produced accurate, reproducible cleavage patterns that are easily discriminated. HLA-DRB1*0410 was the susceptibility allele (RR = 3.26, P = 0.006) and DQB1*0602 appears to be a candidate protective allele (RR = 0.26, P = 0.02) for TGC in the Japanese. None of the HLA-DRB1 and -DQB1 alleles showed a specific tendency for histological type or clinical stage of the tumours. Previous studies based on serotyping methods failed to show these allelic associations. High-resolution genotyping is essential because the peptide-binding domain of MHC class II molecules is determined more precisely by their genotypes than by their serotypes. In addition, inherent technical difficulties and typing errors of up to 25% make serotyping inefficient. Our results suggest that high-resolution genotyping is a useful genetic marker to determine risk for TGC.

Full text

PDF
1348

Images in this article

1349Figure 1
on p.1349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiginger P., Kuzmits R., Kratzig C., Schwarz H. P., Zielinski C. C., Kühböck J., Mayr W. R. HLA antigens and germ-cell tumours. Lancet. 1987 Jan 31;1(8527):276–277. doi: 10.1016/s0140-6736(87)90098-5. [DOI] [PubMed] [Google Scholar]
  2. Ayala F. J. The myth of Eve: molecular biology and human origins. Science. 1995 Dec 22;270(5244):1930–1936. doi: 10.1126/science.270.5244.1930. [DOI] [PubMed] [Google Scholar]
  3. Birkeland S. A., Storm H. H., Lamm L. U., Barlow L., Blohmé I., Forsberg B., Eklund B., Fjeldborg O., Friedberg M., Frödin L. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995 Jan 17;60(2):183–189. doi: 10.1002/ijc.2910600209. [DOI] [PubMed] [Google Scholar]
  4. DeWolf W. C., Lange P. H., Einarson M. E., Yunis E. J. HLA and testicular cancer. Nature. 1979 Jan 18;277(5693):216–217. doi: 10.1038/277216a0. [DOI] [PubMed] [Google Scholar]
  5. Futami S., Aoyama N., Honsako Y., Tamura T., Morimoto S., Nakashima T., Ohmoto A., Okano H., Miyamoto M., Inaba H. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci. 1995 Apr;40(4):814–818. doi: 10.1007/BF02064985. [DOI] [PubMed] [Google Scholar]
  6. Glew S. S., Stern P. L., Davidson J. A., Dyer P. A. HLA antigens and cervical carcinoma. Nature. 1992 Mar 5;356(6364):22–22. doi: 10.1038/356022a0. [DOI] [PubMed] [Google Scholar]
  7. Green A. The epidemiologic approach to studies of association between HLA and disease. II. Estimation of absolute risks, etiologic and preventive fraction. Tissue Antigens. 1982 Apr;19(4):259–268. doi: 10.1111/j.1399-0039.1982.tb01450.x. [DOI] [PubMed] [Google Scholar]
  8. Ichikawa Y., Hashimoto M., Nojima M., Sata M., Fujimoto N., Kyo M., Ishibashi M., Ohshima S., Amemiya H., Fukunishi T. The significant effect of HLA-DRB1 matching on long-term kidney graft outcome. Transplantation. 1993 Dec;56(6):1368–1371. doi: 10.1097/00007890-199312000-00017. [DOI] [PubMed] [Google Scholar]
  9. Kratzik C., Aiginger P., Kuzmits R., Spona J., Kirnbauer M., Seiser A., Mayr W. R. HLA-antigen distribution in seminoma, HCG-positive seminoma and non-seminomatous tumours of the testis. Urol Res. 1989;17(6):377–380. doi: 10.1007/BF00510530. [DOI] [PubMed] [Google Scholar]
  10. Lee J. E., Reveille J. D., Ross M. I., Platsoucas C. D. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer. 1994 Nov 15;59(4):510–513. doi: 10.1002/ijc.2910590413. [DOI] [PubMed] [Google Scholar]
  11. Nomura N., Ota M., Tsuji K., Inoko H. HLA-DQB1 genotyping by a modified PCR-RFLP method combined with group-specific primers. Tissue Antigens. 1991 Aug;38(2):53–59. doi: 10.1111/j.1399-0039.1991.tb01881.x. [DOI] [PubMed] [Google Scholar]
  12. Oliver R. T., Stephenson C. A., Parkinson M. C., Forman D., Atkinson A., Bodmer J., Bodmer W. F. Germ cell tumours of the testicle as a model of MHC influence on human malignancy. Lancet. 1986 Jun 28;1(8496):1506–1506. doi: 10.1016/s0140-6736(86)91544-8. [DOI] [PubMed] [Google Scholar]
  13. Ota M., Seki T., Fukushima H., Tsuji K., Inoko H. HLA-DRB1 genotyping by modified PCR-RFLP method combined with group-specific primers. Tissue Antigens. 1992 Apr;39(4):187–202. doi: 10.1111/j.1399-0039.1992.tb01935.x. [DOI] [PubMed] [Google Scholar]
  14. Ozdemir E., Kakehi Y., Nakamura E., Kinoshita H., Terachi T., Okada Y., Yoshida O. HLA-DRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma. Cancer Res. 1997 Feb 15;57(4):742–746. [PubMed] [Google Scholar]
  15. Perucho M., Goldfarb M., Shimizu K., Lama C., Fogh J., Wigler M. Human-tumor-derived cell lines contain common and different transforming genes. Cell. 1981 Dec;27(3 Pt 2):467–476. doi: 10.1016/0092-8674(81)90388-3. [DOI] [PubMed] [Google Scholar]
  16. Pollack M. S., Livingston P. O. HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosis. Tissue Antigens. 1985 Oct;26(4):262–265. doi: 10.1111/j.1399-0039.1985.tb00970.x. [DOI] [PubMed] [Google Scholar]
  17. Pollack M. S., Vugrin D., Hennessy W., Herr H. W., Dupont B., Whitmore W. F., Jr HLA antigens in patients with germ cell cancers of the testis. Cancer Res. 1982 Jun;42(6):2470–2473. [PubMed] [Google Scholar]
  18. Rukstalis D. B., Bubley G. J., Donahue J. P., Richie J. P., Seidman J. G., DeWolf W. C. Regional loss of chromosome 6 in two urological malignancies. Cancer Res. 1989 Sep 15;49(18):5087–5090. [PubMed] [Google Scholar]
  19. Scorza Smeraldi R., Fabio G., Lazzarin A., Eisera N. B., Moroni M., Zanussi C. HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet. 1986 Nov 22;2(8517):1187–1189. doi: 10.1016/s0140-6736(86)92197-5. [DOI] [PubMed] [Google Scholar]
  20. Senturia Y. D. The epidemiology of testicular cancer. Br J Urol. 1987 Oct;60(4):285–291. doi: 10.1111/j.1464-410x.1987.tb04970.x. [DOI] [PubMed] [Google Scholar]
  21. Thomson G. A review of theoretical aspects of HLA and disease associations. Theor Popul Biol. 1981 Oct;20(2):168–208. doi: 10.1016/0040-5809(81)90009-5. [DOI] [PubMed] [Google Scholar]
  22. Tiercy J. M., Morel C., Freidel A. C., Zwahlen F., Gebuhrer L., Bétuel H., Jeannet M., Mach B. Selection of unrelated donors for bone marrow transplantation is improved by HLA class II genotyping with oligonucleotide hybridization. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7121–7125. doi: 10.1073/pnas.88.16.7121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tollerud D. J., Blattner W. A., Fraser M. C., Brown L. M., Pottern L., Shapiro E., Kirkemo A., Shawker T. H., Javadpour N., O'Connell K. Familial testicular cancer and urogenital developmental anomalies. Cancer. 1985 Apr 15;55(8):1849–1854. doi: 10.1002/1097-0142(19850415)55:8<1849::aid-cncr2820550834>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  24. Yoshimura K., Nishimura K., Miyoshi S., Mizutani S., Mise T., Iwasa K. Father-son testicular cancer. Urol Int. 1993;50(2):108–110. doi: 10.1159/000282464. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES